Abstract 67P
Background
Inflammation is a key factor in the pathogenesis of sarcopenia, a negative prognostic factor in cancer. Higher neutrophil-to-lymphocyte ratio (NLR) is significantly associated with poorer overall survival (OS) across multiple tumor types and can serve as cost-effective surrogate biomarker of a preexisting inflammatory status. We aimed to assess the combined prognostic value of sarcopenia and NLR in IO-treated pt.
Methods
Retrospective analysis of pt with metastatic solid tumors treated with IO within the MP and the ME (off-label/expanded access use) programs at the Catalan Institute of Oncology between Jan’11-Dec’19. Included pt had clinic-analytical data and computed tomography scans performed as standard practice within a month before first IO dose. To analyze sarcopenia, skeletal mass index (SMI) was calculated using Slice-O-Matic software at L3 landmark and sarcopenia was dichotomized according to the median baseline SMI (high versus low). High NLR (>=3) versus low NLR (<3) was calculated in baseline IO-blood test. Kaplan-Meier was used to estimate median OS and log-rank test was used to compare survival curves.
Results
We included 90 pt: the majority were male (66%), <75 years (76%), ECOG <2 (89%), <2 sites of metastases (61%) and had received <3 lines of treatment (93%). Most common tumors were lung (37%) genitourinary (29%), skin (27%) and others (8%, including gynecological, gastrointestinal, sarcomas and SCCHN). Sarcopenia was detected in half of pt of whom 67% had high NLR. OS was 23.5 months (m) in high SMI/low NLR, 12.3m in high SMI/high NLR, 11.8m in low SMI/low NLR and 3 m in low SMI/high NLR groups (p=0.0003). Noteworthy, OS rate at 12 m was 75% (CI 95%; 60-94) in high SMI/low NLR group, whilst in low SMI/high NLR group was 27% (CI 95%; 15-48) (p=0.0001).
Conclusions
The combination of both widely accessible prognostic biomarkers may help in MP and ME programs decision-making, by identifying the subgroup of low SMI/high NLR patients with worse prognosis to better select candidates. Strategies for reducing systemic inflammation and improving skeletal muscle mass are warranted to increase benefits of IO.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
10P - An adapted CGP-based model to interpret POLE mutations in endometrial cancer
Presenter: Rita Trozzi
Session: Cocktail & Poster Display session
Resources:
Abstract
11P - Reconstructing tumour evolution of single cells using both somatic mutations and copy-number alterations
Presenter: Rija Zaidi
Session: Cocktail & Poster Display session
Resources:
Abstract
12P - Swiss-PO: Molecular modelling for precision oncology
Presenter: Fanny Krebs
Session: Cocktail & Poster Display session
Resources:
Abstract
13P - A novel algorithm for predicting variant detectability in oncogenomic analysis
Presenter: Alper Akkuş
Session: Cocktail & Poster Display session
Resources:
Abstract
14P - expHRD: An algorithm for the transcriptome-based estimation of homologous recombination deficiency score
Presenter: Jin-Ku Lee
Session: Cocktail & Poster Display session
Resources:
Abstract
15P - ClinBioNGS: An integrated clinical bioinformatics pipeline for the analysis of somatic NGS cancer panels
Presenter: Xavier Sole
Session: Cocktail & Poster Display session
Resources:
Abstract
16P - Investigation of c-MYC role in DNA-PK-mediated activation of STING pathway in SCLC
Presenter: Caterina de Rosa
Session: Cocktail & Poster Display session
Resources:
Abstract
17P - NRF2 activation promotes HER2-targeted tolerance and resistance in oesophageal adenocarcinoma through metabolic reprogramming to glutathione
Presenter: Wei Zhang
Session: Cocktail & Poster Display session
Resources:
Abstract
18P - AURKB inhibition radiosensitises NSCLC by altering mitotic fate
Presenter: Kathryn Egerton
Session: Cocktail & Poster Display session
Resources:
Abstract
19P - Stratified control study on neuroendocrine differentiation and potential clinical markers in patients with limited-stage small-cell lung cancer
Presenter: Li Liu
Session: Cocktail & Poster Display session
Resources:
Abstract